profit from every $100 of sales.
$0$100
Adaptive Biotechnologies
$29.94+1.98% today
+106.1% in 1 year
1-year low $12.411-year high $30.26
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Adaptive Biotechnologies sold, what it kept, and what it did with the cash.
Sales went from $185 million in 2022 to $277 million in 2025, with -$59.5 million of profit last year.
SalesProfit
Adaptive Biotechnologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Adaptive Biotechnologies | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Adaptive Biotechnologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 98 | 154 | 185 | 170 | 179 | 277 | |
| 76 | 105 | 127 | 95 | 107 | 206 | |
| -153 | -209 | -200 | -202 | -155 | -57 | |
| -144 | -195 | -175 | -189 | -129 | -30 | |
| -146 | -207 | -200 | -225 | -159 | -59 | |
| -1.11 | -1.48 | -1.40 | -1.56 | -1.08 | -0.39 | |
| 77.1% | 68.1% | 68.7% | 55.6% | 59.7% | 74.2% | |
| -155.3% | -135.4% | -108.0% | -118.4% | -86.8% | -20.6% | |
| -148.6% | -134.3% | -108.0% | -132.3% | -89.1% | -21.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,116 | 923 | 857 | 661 | 539 | 513 |
| Cash | 123 | 139 | 90 | 65 | 48 | 70 |
| Total debt | – | – | 108 | 99 | 89 | 79 |
| Total liabilities | 373 | 319 | 393 | 353 | 337 | 288 |
| 743 | 604 | 464 | 308 | 203 | 219 | |
| 131 | 140 | 143 | 144 | 147 | 152 | |
| -16.2% | -27.3% | -27.1% | -41.0% | -40.0% | -12.6% | |
| -19.7% | -34.3% | -43.1% | -73.0% | -78.7% | -27.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -150 | -193 | -184 | -156 | -95 | -46 | |
| 19 | 62 | 16 | 11 | 4 | 3 | |
| -168 | -254 | -200 | -167 | -99 | -49 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 25 | 43 | 55 | 63 | 54 | 51 |
Valuation
- –
- –
- –
- 10.9×
- 17.5×
- –
- –
- -1.0%
- -1.2%
- 0.0%
Profitability
- 74.2%
- -20.6%
- -21.5%
- -7.5%
- -10.8%
- -37.2%
- -24.3%
- -9.8%
- -11.2%
- 31.5%
Growth
- +23.0%
- –
- +50.5%
- –
- +2.0%
Financial health
- –
- 0.96
- 41.1%
- -4.0×
- 3.35
- 3.22
- 0.58
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 23%of 958
Bottom 11%of 888
Top 24%of 889
Bottom 32%of 987
What analysts expect
- Average price target
- $21.25
- Range
- $21.00 – $22.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.13 | -0.16 | +18.8% |
| Feb 5, 2026 | -0.09 | -0.19 | +52.6% |
| Nov 5, 2025 | -0.15 | -0.16 | +6.3% |
| Aug 5, 2025 | -0.17 | -0.24 | +29.2% |
| May 1, 2025 | -0.20 | -0.28 | +28.6% |
| Feb 11, 2025 | -0.23 | -0.27 | +14.8% |
| Nov 7, 2024 | -0.22 | -0.30 | +26.7% |
| Aug 1, 2024 | -0.26 | -0.32 | +18.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
34No pass
Philip Fisher
50No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
42No pass
Questions about Adaptive Biotechnologies
Is Adaptive Biotechnologies a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Adaptive Biotechnologies AI analysis
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. It is in Biotechnology, based in Seattle, WA, United States, with 624 employees.
Does Adaptive Biotechnologies pay a dividend?
No. Adaptive Biotechnologies does not pay a dividend at the moment.
Is Adaptive Biotechnologies stock halal?
Yes. Adaptive Biotechnologies passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Adaptive Biotechnologies stock done over the past year?
Up 106.1% over the past twelve months, to $29.94. It traded between $12.41 and $30.26, close to its high.
Who are Adaptive Biotechnologies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Adaptive Biotechnologies's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.